Back to Journals » OncoTargets and Therapy » Volume 12

Avasimibe inhibits tumor growth by targeting FoxM1-AKR1C1 in osteosarcoma

Authors Wang L, Liu Y, Yu G

Received 15 February 2018

Accepted for publication 6 October 2018

Published 24 January 2019 Volume 2019:12 Pages 815—823

DOI https://doi.org/10.2147/OTT.S165647

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 3

Editor who approved publication: Dr XuYu Yang


Liang Wang,1 Yang Liu,1 Guanzhen Yu2

1Department of Orthopedic, Changzheng Hospital, Shanghai 200003, China; 2Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China

Background: Osteosarcoma (OS) is a rare bone tumor with a high propensity for lung metastasis and poor patient outcomes. It is crucial to identify novel therapeutic strategies and biomarkers.
Patients and methods: ARK1C1 staining was detected in OS specimens, and its clinical significance was assessed. A potential AKR1C1 inhibitor, avasimibe, was used to target AKR1C1.
Results: High expression of AKR1C1 was observed in OS and was associated with poor outcomes for patients with OS. Avasimibe was found to inhibit cell proliferation and tumor growth by reducing the expression of AKR1C1 and FoxM1 in vivo and in vitro.
Conclusion: These findings indicate that AKR1C1 is a promising prognostic factor and may serve as a novel therapeutic target of avasimibe for human OS.

Keywords: osteosarcoma, FoxM1, AKR1C1, immunohistochemistry



Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]